State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.
National Clinical Research Center for Infectious Diseases, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.
mSphere. 2020 Jan 29;5(1):e00791-19. doi: 10.1128/mSphere.00791-19.
Acute liver failure is a severe liver disorder that poses considerable global challenges. Previous studies on R0175 have mainly focused on its psychotropic functions. The current research focused on the protective efficacy of R0175 against acute liver failure caused by d-galactosamine (d-GalN) in rats and further tested the hypothesis that R0175 exerted liver-protective effects by affecting the intestinal microbiota and fecal metabolites and by inhibiting inflammation. We found that oral gavage of R0175 markedly reduced the severity of liver injury in d-GalN-treated rats, as evidenced by decreased serum levels of aspartate aminotransferase (AST) and total bile acids (TBAs) ( < 0.05). Moreover, the plasma concentrations of proinflammatory cytokines (interleukin 1β [IL-1β] and tumor necrosis factor-α [TNF-α]) and chemokines (granulocyte-macrophage colony-stimulating factor [GM-CSF], macrophage chemoattractant protein 1 [MCP-1], chemokine [C-X-C motif] ligand 1 [CXCL1], chemokine [C-C motif] ligand 5 [CCL5], and macrophage inflammatory protein-1α [MIP-1α]) were also markedly reduced ( < 0.05). Pretreatment with R0175 partially reversed the gut microbiota dysbiosis in rats with liver injury by increasing the relative abundances of potentially beneficial bacteria, such as spp., and decreasing the relative abundances of potentially harmful bacteria, such as , spp., and spp. Furthermore, R0175 administration partially improved the metabolic function of the intestinal microbes, as indicated by the decreased level of lithocholic acid found in the feces. Our research investigated the protective and preventive roles of R0175 in a rat model of acute liver failure. The results illustrated that this probiotic strain exhibited protective effects in rats with acute liver failure. Thus, R0175 showed clinical application prospects that required further exploration.
急性肝衰竭是一种严重的肝脏疾病，在全球范围内带来了巨大挑战。先前关于 R0175 的研究主要集中在其精神活性功能上。本研究聚焦于 R0175 对 D-半乳糖胺（D-GalN）诱导的大鼠急性肝衰竭的保护作用，并进一步验证了 R0175 通过影响肠道微生物群和粪便代谢物以及抑制炎症来发挥肝脏保护作用的假设。我们发现，R0175 口服灌胃可显著减轻 D-GalN 处理大鼠的肝损伤严重程度，表现为血清天门冬氨酸氨基转移酶（AST）和总胆汁酸（TBAs）水平降低（<0.05）。此外，促炎细胞因子（白细胞介素 1β [IL-1β]和肿瘤坏死因子-α [TNF-α]）和趋化因子（粒细胞-巨噬细胞集落刺激因子 [GM-CSF]、巨噬细胞趋化蛋白 1 [MCP-1]、趋化因子 [C-X-C 基序]配体 1 [CXCL1]、趋化因子 [C-C 基序]配体 5 [CCL5]和巨噬细胞炎症蛋白 1α [MIP-1α]）的血浆浓度也明显降低（<0.05）。R0175 预处理部分通过增加有益菌（如 spp.）的相对丰度和降低有害菌（如 spp.、 spp. 和 spp.）的相对丰度来逆转肝损伤大鼠的肠道微生物失调。此外，R0175 给药部分改善了肠道微生物的代谢功能，粪便中石胆酸水平降低。本研究探讨了 R0175 在大鼠急性肝衰竭模型中的保护和预防作用。结果表明，该益生菌菌株对急性肝衰竭大鼠具有保护作用。因此，R0175 具有临床应用前景，需要进一步探索。
